Ibrutinib (Imbruvica®) is indicated as a single agent or in combination with obinutuzumab for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL).
|NCPE Assessment Process||Complete|
|Rapid Review Commissioned||06/07/2020|
|Rapid Review Completed||04/08/2020|
|Rapid Review Outcome||A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of Ibrutinib as a single agent or in combination with obinutuzumab for adult patients with previously untreated CLL compared with the current standard of care.|